This document discusses Moffitt Cancer Center's Total Cancer Care program which aims to transform cancer care through a personalized approach. It involves collecting extensive clinical, molecular, and biospecimen data from patients over their lifetime to power research. The goals are to improve outcomes through early detection, personalized treatment, and clinical trials matching. Moffitt has established an extensive biorepository and informatics platform to integrate data from over 78,000 consented patients to enable precision oncology research.
di Pier Giuseppe Pelicci, MD-PhD, Istituto Europeo di Oncologia IEO, Università degli Studi di Milano.
Slide per l'intervento tenuto in Fondazione Giannino Bassetti in occasione del primo incontro del ciclo "La medicina di precisione", primo progetto dalla convenzione tra Università di Pavia e Fondazione Bassetti.
12 marzo 2018
FDA NGS and Big Data Conference September 2014Warren Kibbe
Presentation for the FDA NGS and Big Data Conference September 2014 held on the NIH campus. NCI initiatives, including Cancer Genomics Data Commons, NCI Cloud Pilots, big data issues for cancer
di Pier Giuseppe Pelicci, MD-PhD, Istituto Europeo di Oncologia IEO, Università degli Studi di Milano.
Slide per l'intervento tenuto in Fondazione Giannino Bassetti in occasione del primo incontro del ciclo "La medicina di precisione", primo progetto dalla convenzione tra Università di Pavia e Fondazione Bassetti.
12 marzo 2018
FDA NGS and Big Data Conference September 2014Warren Kibbe
Presentation for the FDA NGS and Big Data Conference September 2014 held on the NIH campus. NCI initiatives, including Cancer Genomics Data Commons, NCI Cloud Pilots, big data issues for cancer
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
Digital Pathology: Precision Medicine, Deep Learning and Computer Aided Inter...Joel Saltz
In this presentation, I will survey the development of Digital Pathology methodology beginning with the 1997 virtual microscope prototype at Hopkins to current tools, methods and algorithms designed to display, analyze and classify whole slide imaging data. I will describe methods, tools and algorithms to extract information from Pathology images. These tools include ability to traverse whole slide images, segment nuclei, carry out deep learning region classification and characterize relationship between extracted features and morphological structures. I will also describe some of the research efforts that motivate development of these tools, the role Pathomics is playing in precision medicine research as well as the impact of Pathology Informatics on clinical practice and health care quality.
Presentation at the Department of Biomedical Informatics, University Pittsburgh Medical Center, April 27, 2018
Feature story from the Garvan Institute of Medical Research's April 2013 issue of Breakthrough newsletter. More at https://www.garvan.org.au/news-events/newsletters
Twenty Years of Whole Slide Imaging - the Coming Phase ChangeJoel Saltz
I surveyed the development of Digital Pathology methodology beginning with the 1997 virtual microscope prototype at Hopkins (PMC2233368) to current tools, methods and algorithms designed to display, analyze and classify whole slide imaging data. I will describe the capabilities of current methods, describe how these methods are likely to evolve and how they will be likely to impact Pathology research and practice.
Towards Digitally Enabled Genomic Medicine: the Patient of The FutureLarry Smarr
12.02.22
Invited Speaker
Hacking Life
TTI/Vanguard Conference
Title: Towards Digitally Enabled Genomic Medicine: the Patient of The Future
San Jose, CA
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Andrew Aijian
At DeciBio Consulting, we track the immuno-oncology (I/O) biomarker and technology landscape closely. Our analysis of biomarkers from ~1,000 immuno-oncology clinical trials and discussions with oncologists, pathologists, and KOLs reveals some key insights for diagnostic manufacturers to consider to address the I/O market.
Advancing Innovation and Convergence in Cancer Research: US Federal Cancer Mo...Jerry Lee
Special Seminar at the 8th Taiwan Biosignatures Workshop to share overall work of NCI's Center for Strategic Scientific Initiatives since 2003 as well as CSSI's influence on select projects initiated by the 2016 WH Cancer Moonshot Task Force that include Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, International Cancer Proteogenome Consortium, and the Blood Profiling Atlas in Cancer (BloodPAC) commons.
Phillip Payne summarizes the key points of the CITIH 2011 Conference
Bridging Health IT & Innovation: Next steps in advancing healthcare through shared strengths and strategies.
Organ Specific Proteomics as Presented by Paul Kearney, PhD; CSO, Integrated Diagnostics at the 2010 Personalized Health Care National Conference at Ohio State.
Next Generation Companion Diagnostics; Adoption, Drivers, and Moderators of N...Andrew Aijian
Analysis and synthesis of a pulse survey conducted across >140 oncologists, pathologists, and lab directors regarding current adoption and trends associated with emerging oncology biomarkers and companion diagnostics (CDx), with an emphasis on next-generation sequencing (NGS)-based CDx.
Digital Pathology: Precision Medicine, Deep Learning and Computer Aided Inter...Joel Saltz
In this presentation, I will survey the development of Digital Pathology methodology beginning with the 1997 virtual microscope prototype at Hopkins to current tools, methods and algorithms designed to display, analyze and classify whole slide imaging data. I will describe methods, tools and algorithms to extract information from Pathology images. These tools include ability to traverse whole slide images, segment nuclei, carry out deep learning region classification and characterize relationship between extracted features and morphological structures. I will also describe some of the research efforts that motivate development of these tools, the role Pathomics is playing in precision medicine research as well as the impact of Pathology Informatics on clinical practice and health care quality.
Presentation at the Department of Biomedical Informatics, University Pittsburgh Medical Center, April 27, 2018
Feature story from the Garvan Institute of Medical Research's April 2013 issue of Breakthrough newsletter. More at https://www.garvan.org.au/news-events/newsletters
Twenty Years of Whole Slide Imaging - the Coming Phase ChangeJoel Saltz
I surveyed the development of Digital Pathology methodology beginning with the 1997 virtual microscope prototype at Hopkins (PMC2233368) to current tools, methods and algorithms designed to display, analyze and classify whole slide imaging data. I will describe the capabilities of current methods, describe how these methods are likely to evolve and how they will be likely to impact Pathology research and practice.
Towards Digitally Enabled Genomic Medicine: the Patient of The FutureLarry Smarr
12.02.22
Invited Speaker
Hacking Life
TTI/Vanguard Conference
Title: Towards Digitally Enabled Genomic Medicine: the Patient of The Future
San Jose, CA
Next-Generation Immuno-Oncology Biomarkers: Insights for Developing Companion...Andrew Aijian
At DeciBio Consulting, we track the immuno-oncology (I/O) biomarker and technology landscape closely. Our analysis of biomarkers from ~1,000 immuno-oncology clinical trials and discussions with oncologists, pathologists, and KOLs reveals some key insights for diagnostic manufacturers to consider to address the I/O market.
Advancing Innovation and Convergence in Cancer Research: US Federal Cancer Mo...Jerry Lee
Special Seminar at the 8th Taiwan Biosignatures Workshop to share overall work of NCI's Center for Strategic Scientific Initiatives since 2003 as well as CSSI's influence on select projects initiated by the 2016 WH Cancer Moonshot Task Force that include Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, International Cancer Proteogenome Consortium, and the Blood Profiling Atlas in Cancer (BloodPAC) commons.
Phillip Payne summarizes the key points of the CITIH 2011 Conference
Bridging Health IT & Innovation: Next steps in advancing healthcare through shared strengths and strategies.
Organ Specific Proteomics as Presented by Paul Kearney, PhD; CSO, Integrated Diagnostics at the 2010 Personalized Health Care National Conference at Ohio State.
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
Cancer Moonshot, Data sharing and the Genomic Data CommonsWarren Kibbe
Gave the inaugural Informatics Grand Rounds at City of Hope on September 8th. NIH Commons, Genomic Data Commons, NCI Cloud Pilots, Cancer Moonshot and rationale for changing incentives around data sharing all discussed.
Bladder Cancer Diagnostic-Initial Team ProjectSagar Desai
A mini-project to find biomarkers for bladder cancer diagnosis. We narrowed down our list of viable candidates down to three that could be used in combination to provide sensitivity and specificity values greater than 94%. Furthermore, we calculated long-term monitoring and payor costs as well as potential profit.
Using real-world evidence to investigate clinical research questionsKarin Verspoor
Adoption of electronic health records to document extensive clinical information brings with it the opportunity to utilise that information to support clinical research, and ultimately to support clinical decision making. In this talk, I discuss both these opportunities and the challenges that we face when working with real-world clinical data, and introduce some of the strategies that we are adopting to make this data more usable, and to extract more value from it. I specifically discuss the use of natural language processing to transform clinical documentation into structured data for this purpose.
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
Leveraging Publicly Accessible Clinical Trails Data Sharing, Dissemination an...Vaticle
In the broader realm of the advancement of science and the betterment of the human condition, there are several purported benefits for sharing clinical trials and research data. The scientific community has just begun to embrace open-access datasets to build their knowledge base, gain insight into new discoveries, and generate novel data-driven hypotheses that were not initially formulated in the studies. With the increasing amount of clinical trial data available, comes the need to leverage a multitude of shared datasets. Your knowledge base needs to facilitate discovery across research domains.
This talk highlights the data sharing, dissemination, and repurposing of clinical and molecular studies generated by government-funded research consortia. Further, we are building a new knowledge base resource, IMMGRAKN to facilitate translational discovery from crowd-sourced clinical trials data in ImmPort (www.immport.org), an NIH-NIAID funded open-access immunology database and analysis portal. The case studies demonstrating the use of IMMGRAKN will be discussed
DOE-NCI Pilots presentation at the Frederick National Laboratory Advisory Com...Warren Kibbe
May 2016 FNLAC presentation of the DOE-NCI partnership around three pilots focused on existing projects in NCI and existing NSCI directives and activities in DOE.
TCGC The Clinical Genome Conference 2015Nicole Proulx
Bio-IT World and Cambridge Healthtech Institute are again proud to host the Fourth Annual TCGC: The Clinical Genome Conference, inviting stakeholders impacting clinical genomics to share new findings and solutions for advancing the applications of clinical genome medicine.
5th Tumor Models Boston July 2017 BrochureDiane McKenna
Tumor Models Boston 2017 will address the preclinical & clinical developments of the most promising therapies including targeted therapies, check-point inhibitors & CAR-T therapies and how these findings can be utilized to bridge the gap between preclinical and clinical studies.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Overview on Edible Vaccine: Pros & Cons with Mechanism
Dalton
1. Transformation to Value-Based Personalized Healthcare: Cancer as a Model William S. Dalton, PhD, MDPresident, CEO & Center DirectorMoffitt Cancer Center & Research InstituteTampa, Florida
2. Total Cancer Care: A Personalized Approach to a Patient’s Health Journey Populations at Risk Intervention Diagnosis Survivorship Prognosis Relapsed Disease Treatment – Behavioral Research – Psychosocial & Palliative Care – Family Needs – Health Outcomes – Risk Factors – Genetics – Early Detection – Health Disparities – Recurrence Therapy – Drug Discovery – Adaptive Trial Design – Prevention – Lifestyle/Nutrition – Education – Genomics/Proteomics – Imaging Modalities – Nanotechnology – Primary Therapy • Multimodality • Target Based – Post Therapy • Surveillance – Clinical Trials Matching – Molecular Oncology – Biomarker Analysis (http://www.hhs.gov/myhealthcare/news/phc_2008_report.pdf; pg 243)
3. The Necessary Components Clinically annotated bio-repository for tumor and normal specimens Partnership among researchers, clinicians, regulators, policy makers, and patients to design an integrated information network system
4.
5. Can we study your tumor using molecular technology?
20. The Approach Improved Medical Practice Create a delivery system that will integrate new technologies into the standard of care and develop evidence-based guidelines for the treatment of cancer.
32. The HRI Platform Defined An integrated information platform that will create real-time relationships and associations from disparate data sources needed to create new knowledge for improved patient treatments, outcomes and prevention.
33. Core Data Aggregation andStorage Source Systems Some representative examples of business level data domains Patient Cohort Examples Demographics Cancer Stage Diagnosis Treatment Labs Drugs Integrated Data Warehouse Data Factory Implementation Data Mapping Data Sourcing Data Profiling Data Modeling Data Linkage HRI Solution: Conceptual Architecture Front End Information Delivery Newly Diagnosed, Primary Pancreatic, having CEL File Cancer Registry LabVantage Capstone Primary Breast Cancer, Survival Time >30 months, Disease Stage 1-4, Diagnosed with Type 2 Diabetes, currently on Metaformin Female with myelodysplastic syndrome, currently taking vidaza as Ist course chemotherapy, initially diagnosed in 2007-2008 CEL Files Galvanon 3M
37. Tissue specimen data available – drill down capabilities to 5 levels of detailed data elements.
38. The Need for Linked Queries Patient 1 Patient 2 1-1-2009 Lung Upper Lobe 1-1-2010 Lung Upper Lobe 1-1-2010 Adenocarcinoma NOS LINK 6-30-2010 Adenocarcinoma NOS 6-30-2010 Skin Trunk
52. How is Moffitt Benefiting from the RIE? Using the TCC Database to match patients to clinical trials Right treatment for the right patient using molecular markers for patient selection Development of Comparative Effectiveness Research Infrastructure What works best for whom Integration of molecular, clinical, biospecimen and patient self-report data Gene expression data, Exome sequencing data, SNP/CNV data for new diagnostics, prognostic response and new drug discovery
53.
54. High-Throughput Sequencing Exome Sequencing 361 breast and ovary biospecimens sequenced at BGI Whole exome sequencing (Agilent SureSelect 38MB kit ) Raw and analyzed data currently available 4,000 samples being sequenced at BGI ~1,400 genes 500 lung, 400 kidney, 300 colon 150 each: uterus, pancreas, ovary, endometrium 100 each: heme malignancies, melanoma, breast 50 each: stomach, esphagus, liver, cervix, soft tissue, rectum, anus 650 undecided Whole genome sequencing: Melanoma 13 match pairs at Wash U Genome Inst.
55.
56. Linked to TCC gene expression array and clinical follow-up databases
124. Ultimate Goal of New Trials To incorporate molecular characteristics of the tumor, as well as the patient’s genetic background, into an individualized treatment plan to maximize clinical benefit to the patient from specific anti-tumor agents.
125.
126. Phase 2 R115777 in elderly AML with specific 2-gene ratio (active)